Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NCT02953457 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

BRCA1 Gene Mutation
BRCA2 Gene Mutation
Ovarian Serous Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: Durvalumab
OTHER: Laboratory Biomarker Analysis
DRUG: Olaparib
BIOLOGICAL: Tremelimumab

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]